Exelixis (EXEL) Kev ntsuas ntawv
AI kev txhais lus: EXEL
AI tshaj tawm tus nqi hom phiaj rau hnub lag luam tom ntej, kawg lub lis thiab kawg hli. Kev hloov kho raug ntsuas los ntawm tus nqi tshiab. Cov no yog kev ntsuas xav tau, tsis yog kev pab cuam lag luam.
Nqi hauv 6 hli dhau los
Premium qhia AI lub hom phiaj nqi rau 1 hnub, 1 lim tiam thiab 1 hli rau tus no thiab txhua tus stock lwm tus.
Qhib Premium🔒 Kev ntsuas kev txav chav
Kev ntsuas kev txav chav — txhua kev ntsuas dhau los nyob ze rau qhov kawg tiag tiag — yog ib feem ntawm Premium.
Qhib PremiumTxog lub tuam txhab no
Exelixis, Inc. is a biotechnology company specializing in the development of promising small-molecule drugs for the treatment of cancer and other serious diseases, including kidney disease, thyroid cancer, and advanced melanoma. The company also establishes strategic partnerships with other pharmaceutical and biotechnology firms.
